Featured Research

from universities, journals, and other organizations

Drug combination extends survival by more than a year in metastatic prostate cancer

Date:
June 1, 2014
Source:
Dana-Farber Cancer Institute
Summary:
Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to hormone-blockers, report scientists. The dramatic results in a multi-center phase III trial should change the way physicians have routinely treated such patients since the 1950s, they said.

Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to hormone-blockers, report scientists from Dana-Farber Cancer Institute and the Eastern Co-operative Oncology Group.

Related Articles


The dramatic results in a multi-center phase III trial should change the way physicians have routinely treated such patients since the 1950s, they said.

"This is the first study to identify a strategy that prolongs survival in newly diagnosed, metastatic prostate cancer," said Christopher J. Sweeney, M.B.B.S, of Dana-Farber's Lank Center for Genitourinary Oncology. He presented the results of the trial June 1, 2014 at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

"The benefit is substantial and warrants this being a new standard treatment for men who have high-extent disease and are fit for chemotherapy," added Sweeney, principal investigator of the E3805 National Cancer Institute-funded study.

"The prolongation in survival seen in the prostate cancer patients participating in Dr. Sweeney's study is very impressive, dramatically longer than the typical 2-6 month prolongation typically observed in successful studies of other metastatic adult solid tumors," said Bruce E. Johnson, MD, Dana-Farber's chief clinical research officer.

In current practice, men newly diagnosed with prostate cancer that has spread widely, and whose cancer depends on male hormones to grow, are started on hormone-blocking medications -- androgen deprivation therapy (ADT). Most tumors eventually outgrow their need for hormones and the cancer progresses. Only then do patients begin chemotherapy.

The new trial tested Sweeney's hypothesis that immediately hitting the cancer with chemotherapy in addition to hormone treatment would impair the tumor cells' ability to repair damage, delaying the development of resistance.

The study enrolled 790 men newly diagnosed with metastatic disease; they were randomized to receive ADT alone or ADT with docetaxel (brand name Taxotereฎ) over 18 weeks. In the ADT-only group, 124 patients were given docetaxel when their cancer worsened. In the ADT-plus-docetaxel group, 45 patients whose disease progressed received additional docetaxel.

At a median follow-up of 29 months, 136 patients in the ADT-only group had died versus 101 in the group that received both drugs. This translated into a median overall survival of 57.6 months for men who received early chemotherapy compared with 44 months in the group given ADT as the only initial treatment -- more than a year of additional life.

In the 520 patients who had high-extent disease (whose cancer had spread to major organs and/or the bones), treatment with ADT plus docetaxel had an even greater benefit: these men had a median overall survival of 49.2 months versus 32.2 in the ADT-only group -- a difference of 17 months.

Earlier results of the trial were made public by the NCI in December 2013 because of the strong positive findings. Sweeney's presentation at ASCO covers updated and more detailed results.

Most of the striking survival benefit with early use of docetaxel was found in men with a high burden of metastatic disease. Sweeney said more time is needed to assess the benefit of the drug combination in the men with lesser burdens of disease, as their median survival has not yet been reached.

The most serious side effects were neutropenic fever and neuropathy; one patient died as a result of treatment.

The addition of docetaxel not only lengthened survival but delayed disease progression as measured by an increase in prostate-specific antigen (PSA), the appearance of new metastases, or worsening symptoms. The men receiving docetaxel had an average of 32.7 months before the cancer progressed by worsening scan results or symptoms, compared to 19.8 months for hormone therapy alone.

"This study shows that early chemotherapy increases the chances that certain patients with metastatic prostate cancer have a longer time without symptoms from cancer, and also live longer," Sweeney said.


Story Source:

The above story is based on materials provided by Dana-Farber Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Dana-Farber Cancer Institute. "Drug combination extends survival by more than a year in metastatic prostate cancer." ScienceDaily. ScienceDaily, 1 June 2014. <www.sciencedaily.com/releases/2014/06/140601150645.htm>.
Dana-Farber Cancer Institute. (2014, June 1). Drug combination extends survival by more than a year in metastatic prostate cancer. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2014/06/140601150645.htm
Dana-Farber Cancer Institute. "Drug combination extends survival by more than a year in metastatic prostate cancer." ScienceDaily. www.sciencedaily.com/releases/2014/06/140601150645.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) — An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins